Inactive Instrument

News Melinta Therapeutics, Inc. Other OTC

Equities

Summary

Unlock all the news: Be the first to know and act before the market!

Melinta Therapeutics, LLC Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 Trial and Recently Approved Rezafungin CLSI Breakpoints for Candida Glabrata and Candida Auris	05-23	CI
Venatorx Pharmaceuticals and Melinta Therapeutics Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam	02-23	CI
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection	02-20	CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	12-05	CI
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO (Rezafungin for Injection)	02/10/23	CI
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens	10/07/23	CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (Rezafungin for Injection) for the Treatment of Candidemia and Invasive Candidiasis	22/03/23	CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis	25/01/23	CI
Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet	28/11/22	CI
Melinta Therapeutics, Inc. Acquires U.S. Rights to TOPROL-XL® (Metoprolol Succinate) from New American Therapeutics, Inc	06/04/22	CI
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™	20/09/21	CI
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)	07/07/21	CI
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy	06/07/21	CI
Melinta Therapeutics, Inc. Announces Appointment of Susan Blum as Chief Financial Officer. Effective July 1, 2021	29/06/21	CI
Melinta Therapeutics, LLC Appoints John Harlow as Chief Commercial Officer	29/03/21	CI
Melinta Therapeutics, LLC Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections	15/03/21	CI
Melinta Therapeutics, LLC Appoints Kristen Allgor as Chief Human Resources Officer	16/11/20	CI
Melinta Therapeutics Announces Executive Changes	03/08/20	CI
Melinta Therapeutics Announces CEO Changes	03/08/20	CI
Melinta Therapeutics, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	23/06/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Melinta Therapeutics, Inc. Other OTC

Equities

Summary

Filters